{"disease":{"id":"cardiorenal-syndrome-type-1","name":"cardiorenal syndrome type 1"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06030843","title":"The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Chulalongkorn University","has_results":false},{"nct_id":"NCT06065163","title":"Ultrasound Guided Diuretic Therapy in Type 1 Cardiorenal Syndrome","phase":"NA","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Instituto Nacional de Cardiologia Ignacio Chavez","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}